Caribou Biosciences (CRBU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 17, 2026, with several key proposals up for vote.
Shareholders are encouraged to vote promptly via internet or telephone for convenience.
Voting matters and shareholder proposals
Election of Andrew Guggenhime, David Johnson, and Nancy Whiting as Class II directors is proposed.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal to amend the certificate of incorporation to provide officer exculpation from certain fiduciary duty breaches.
Approval sought for potential adjournment of the meeting if more time is needed for voting or to establish a quorum.
Board of directors and corporate governance
Board recommends voting in favor of all proposals presented at the annual meeting.
Latest events from Caribou Biosciences
- Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA.CRBU
Jefferies Global Healthcare Conference 20264 Jun 2026 - Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials.CRBU
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Off-the-shelf CAR-T therapies show strong clinical promise and scalable commercial potential.CRBU
Bank of America Global Healthcare Conference 202613 May 2026 - Net loss narrowed to $25.2M, cash of $118.6M may fund operations into 2H 2027.CRBU
Q1 20267 May 2026 - Key proposals include director elections, auditor ratification, and officer exculpation.CRBU
Proxy filing1 May 2026 - 2026 meeting covers director elections, auditor ratification, and officer exculpation proposals.CRBU
Proxy filing24 Apr 2026 - Director elections, auditor ratification, and officer exculpation amendment up for vote.CRBU
Proxy filing24 Apr 2026 - 2026 meeting covers director elections, auditor ratification, and officer exculpation amendment.CRBU
Proxy filing10 Apr 2026 - Pivotal trial planning advances for vispa-cel, with global commercialization and funding strategies outlined.CRBU
Leerink Global Healthcare Conference 202610 Mar 2026